Literature DB >> 26385640

A novel mouse model that recapitulates adult-onset glycogenosis type 4.

H Orhan Akman1, Valentina Emmanuele2, Yasemin Gülcan Kurt3, Bülent Kurt4, Tatiana Sheiko5, Salvatore DiMauro2, William J Craigen6.   

Abstract

Glycogen storage disease type IV (GSD IV) is a rare autosomal recessive disorder caused by deficiency of the glycogen-branching enzyme (GBE). The diagnostic hallmark of the disease is the accumulation of a poorly branched form of glycogen known as polyglucosan (PG). The disease is clinically heterogeneous, with variable tissue involvement and age at onset. Complete loss of enzyme activity is lethal in utero or in infancy and affects primarily the muscle and the liver. However, residual enzyme activity as low as 5-20% leads to juvenile or adult onset of a disorder that primarily affects the central and peripheral nervous system and muscles and in the latter is termed adult polyglucosan body disease (APBD). Here, we describe a mouse model of GSD IV that reflects this spectrum of disease. Homologous recombination was used to knock in the most common GBE1 mutation p.Y329S c.986A > C found in APBD patients of Ashkenazi Jewish decent. Mice homozygous for this allele (Gbe1(ys/ys)) exhibit a phenotype similar to APBD, with widespread accumulation of PG. Adult mice exhibit progressive neuromuscular dysfunction and die prematurely. While the onset of symptoms is limited to adult mice, PG accumulates in tissues of newborn mice but is initially absent from the cerebral cortex and heart muscle. Thus, PG is well tolerated in most tissues, but the eventual accumulation in neurons and their axons causes neuropathy that leads to hind limb spasticity and premature death. This mouse model mimics the pathology and pathophysiologic features of human adult-onset branching enzyme deficiency.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26385640      PMCID: PMC4634380          DOI: 10.1093/hmg/ddv385

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  41 in total

1.  Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease.

Authors:  Erica Tiberia; Julie Turnbull; Tony Wang; Alessandra Ruggieri; Xiao-Chu Zhao; Nela Pencea; Johan Israelian; Yin Wang; Cameron A Ackerley; Peixiang Wang; Yan Liu; Berge A Minassian
Journal:  J Biol Chem       Date:  2012-06-05       Impact factor: 5.157

2.  Living Donor Liver Transplantation in a Korean Child with Glycogen Storage Disease Type IV and a GBE1 Mutation.

Authors:  Hye Ryun Ban; Kyung Mo Kim; Joo Young Jang; Gu-Hwan Kim; Han-Wook You; Kyungeun Kim; Eunsil Yu; Dae Yeon Kim; Ki Hun Kim; Young Joo Lee; Sung Gyu Lee; Young Nyun Park; Hong Koh; Ki Sup Chung
Journal:  Gut Liver       Date:  2009-03-31       Impact factor: 4.519

3.  Generation of a novel mouse model that recapitulates early and adult onset glycogenosis type IV.

Authors:  H Orhan Akman; Tatiana Sheiko; Stacey K H Tay; Milton J Finegold; Salvatore Dimauro; William J Craigen
Journal:  Hum Mol Genet       Date:  2011-08-19       Impact factor: 6.150

4.  Impaired glucose tolerance and predisposition to the fasted state in liver glycogen synthase knock-out mice.

Authors:  Jose M Irimia; Catalina M Meyer; Caron L Peper; Lanmin Zhai; Cheryl B Bock; Stephen F Previs; Owen P McGuinness; Anna DePaoli-Roach; Peter J Roach
Journal:  J Biol Chem       Date:  2010-02-23       Impact factor: 5.157

5.  Glycogen branching enzyme deficiency in quarter horse foals.

Authors:  S J Valberg; T L Ward; B Rush; H Kinde; H Hiraragi; D Nahey; J Fyfe; J R Mickelson
Journal:  J Vet Intern Med       Date:  2001 Nov-Dec       Impact factor: 3.333

6.  Adult polyglucosan body disease: Natural History and Key Magnetic Resonance Imaging Findings.

Authors:  Fanny Mochel; Raphael Schiffmann; Marjan E Steenweg; Hasan O Akman; Mary Wallace; Frédéric Sedel; Pascal Laforêt; Richard Levy; J Michael Powers; Sophie Demeret; Thierry Maisonobe; Roseline Froissart; Bruno Barcelos Da Nobrega; Brent L Fogel; Marvin R Natowicz; Catherine Lubetzki; Alexandra Durr; Alexis Brice; Hanna Rosenmann; Varda Barash; Or Kakhlon; J Moshe Gomori; Marjo S van der Knaap; Alexander Lossos
Journal:  Ann Neurol       Date:  2012-09       Impact factor: 10.422

7.  Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III.

Authors:  Baodong Sun; Keri Fredrickson; Stephanie Austin; Adviye A Tolun; Beth L Thurberg; William E Kraus; Deeksha Bali; Yuan-Tsong Chen; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2012-12-27       Impact factor: 4.797

8.  Polyglucosan body disease simulating amyotrophic lateral sclerosis.

Authors:  T D McDonald; P L Faust; C Bruno; S DiMauro; J E Goldman
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

9.  Fatal infantile neuromuscular presentation of glycogen storage disease type IV.

Authors:  Stacey K H Tay; Hasan O Akman; Wendy K Chung; Michael G Pike; Francesco Muntoni; Arthur P Hays; Sara Shanske; Stephanie J Valberg; James R Mickelson; Kurenai Tanji; Salvatore DiMauro
Journal:  Neuromuscul Disord       Date:  2004-04       Impact factor: 4.296

Review 10.  Adult polyglucosan body disease associated with an extrapyramidal syndrome.

Authors:  N P Robertson; S Wharton; J Anderson; N J Scolding
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-11       Impact factor: 10.154

View more
  7 in total

1.  Skeletal Muscle Glycogen Chain Length Correlates with Insolubility in Mouse Models of Polyglucosan-Associated Neurodegenerative Diseases.

Authors:  Mitchell A Sullivan; Silvia Nitschke; Evan P Skwara; Peixiang Wang; Xiaochu Zhao; Xiao S Pan; Erin E Chown; Travis Wang; Ami M Perri; Jennifer P Y Lee; Francisco Vilaplana; Berge A Minassian; Felix Nitschke
Journal:  Cell Rep       Date:  2019-04-30       Impact factor: 9.423

2.  A Modified Enzymatic Method for Measurement of Glycogen Content in Glycogen Storage Disease Type IV.

Authors:  Haiqing Yi; Quan Zhang; Chunyu Yang; Priya S Kishnani; Baodong Sun
Journal:  JIMD Rep       Date:  2016-06-26

3.  Guaiacol as a drug candidate for treating adult polyglucosan body disease.

Authors:  Or Kakhlon; Igor Ferreira; Leonardo J Solmesky; Netaly Khazanov; Alexander Lossos; Rafael Alvarez; Deniz Yetil; Sergey Pampou; Miguel Weil; Hanoch Senderowitz; Pablo Escriba; Wyatt W Yue; H Orhan Akman
Journal:  JCI Insight       Date:  2018-09-06

4.  Targeting Gys1 with AAV-SaCas9 Decreases Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models.

Authors:  Emrah Gumusgoz; Dikran R Guisso; Sahba Kasiri; Jun Wu; Matthew Dear; Brandy Verhalen; Silvia Nitschke; Sharmistha Mitra; Felix Nitschke; Berge A Minassian
Journal:  Neurotherapeutics       Date:  2021-04-08       Impact factor: 7.620

5.  Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV.

Authors:  Haiqing Yi; Fengqin Gao; Stephanie Austin; Priya S Kishnani; Baodong Sun
Journal:  Mol Genet Metab Rep       Date:  2016-10-04

6.  GYS1 or PPP1R3C deficiency rescues murine adult polyglucosan body disease.

Authors:  Erin E Chown; Peixiang Wang; Xiaochu Zhao; Justin J Crowder; Jordan W Strober; Mitchell A Sullivan; Yunlin Xue; Cody S Bennett; Ami M Perri; Bret M Evers; Peter J Roach; Anna A Depaoli-Roach; H Orhan Akman; Bartholomew A Pederson; Berge A Minassian
Journal:  Ann Clin Transl Neurol       Date:  2020-10-09       Impact factor: 4.511

Review 7.  Lipids in Pathophysiology and Development of the Membrane Lipid Therapy: New Bioactive Lipids.

Authors:  Manuel Torres; Sebastià Parets; Javier Fernández-Díaz; Roberto Beteta-Göbel; Raquel Rodríguez-Lorca; Ramón Román; Victoria Lladó; Catalina A Rosselló; Paula Fernández-García; Pablo V Escribá
Journal:  Membranes (Basel)       Date:  2021-11-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.